Immunology Market to Reach USD 184.21 Billion by 2029; Rising Biosimilars Penetration to Foster Market Progress

The global immunology market size is expected to exhibit remarkable growth by reaching USD 184.21 billion by 2029. Fortune Business Insights™ in its report titled “Immunology Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Monoclonal Antibody (mAb), Fusion Proteins, Immunosuppressants, and Others), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2022-2029” observes that the market size in 2021 stood at USD 97.93 billion and touched USD 104.12 billion in 2022. The market is expected to exhibit a CAGR of 8.5% during 2022-2029. Increasing Research & Development (R&D) investments and biosimilars penetration are expected to foster this industry’s progress.

Increasing Efforts by Major Players Positively Impacted Market Progress During the Pandemic

This market was positively impacted during the COVID-19 pandemic due to increasing efforts by several key players. The sudden spike in COVID-19 infections forced governments to impose stringent norms on travel, transport, and production activities to stop infection spread. These norms resulted in supply chain disruptions and lack of raw materials. However, major players deployed part-time shifts, industrial automation, and reduced capacities to reduce infection spread and continue their business. Further, the post-COVID-19 phase empowered companies to operate efficiently and boost productivity. Companies opted for automation to recover losses and boost sales. These factors elevated market growth during the pandemic.

Pfizer Inc. Received U.S.FDA Approval for its CIBINQO, Empowering the Company to Elevate its Brand Image

Pfizer Inc.’s CIBINQO received the U.S. FDA in January 2022. This approval may empower Pfizer Inc. to enhance its product offerings and elevate its sales. In addition, this strategy may empower Pfizer to boost its brand image.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/immunology-market-100657

Rising Autoimmune Diseases to Boost Market Progress

Immunology drugs are medicines capable of elevating and suppressing the immune system. Increasing autoimmune disorders globally are likely to fuel market progress. For example, as per National Stem Cell Foundation’s research, nearly 4% of the global population suffers from at least one among 80 autoimmune diseases. Further, the rising adoption of these drugs among the global population and the increasing announcement of efficient and better drugs are likely to enhance product adoption. Moreover, the increasing adoption of autoimmune drugs in developing and developed nations may drive the immunology market growth.

Key Players Deploy Acquisitions to Strengthen their Product Portfolio

The prominent companies operating in the market devise acquisitions to boost their product offerings. For example, Pfizer completed the acquisition of Arena Pharmaceuticals in February 2022 to develop effective therapies to cure several immune-inflammatory diseases in patients. This strategy enabled Pfizer to strengthen its product portfolio and boost its brand image. Further, several market players devise innovations, mergers, novel product announcements, partnerships, research and development, and industrial automation to reinforce their market position.

Notable Industry Development

• December 2021- Amgen Inc. received the U.S. FDA approval for Otezla to treat plaque psoriasis in adult patients.

List of Key Players Profiled in the Report

• AbbVie, Inc. (U.S.)


• Janssen Global Services, LLC (U.S.)


• Eli Lilly and Company (U.S.)


• Novartis AG (Switzerland)


• Pfizer Inc. (U.S.)


• Bristol-Myers Squibb Company (U.S.)


• Merck Sharp & Dohme Corp. (U.S.)


• F. Hoffmann-La Roche Ltd. (Switzerland)


• Amgen Inc. (U.S.)


• Astellas Pharma Inc. (Japan)


• UCB SA (Belgium)

Further Report Findings

• The market in North America stood at USD 54.04 billion in 2021 and is expected to gain a huge portion of the global immunology market share in the coming years. The presence of developed healthcare infrastructure in the region is expected to boost immunology adoption.


• Further, increasing diagnosis rates among patients may surge the demand for immunology. These factors may propel market progress in the region.


• In Europe, the increasing prevalence of autoimmune diseases may hamper the adoption of immunology drugs.

Table of Segmentation